Journal of Cosmetics, Dermatological Sciences and Applications

Volume 4, Issue 2 (March 2014)

ISSN Print: 2161-4105   ISSN Online: 2161-4512

Google-based Impact Factor: 0.33  Citations  

A Double-Blind, Placebo Controlled Clinical Trial Evaluating the Efficacy and Safety of a New Skin Whitening Combination in Patients with Chloasma

HTML  Download Download as PDF (Size: 475KB)  PP. 92-98  
DOI: 10.4236/jcdsa.2014.42014    6,022 Downloads   9,677 Views  Citations

ABSTRACT

Melasma (or chloasma) is a hyperpigmentation disorder predominantly affecting sun-exposed skin in women, and is often refractory to treatment. The objective was to evaluate the efficacy and safety of a new whitening formula for the treatment of chloasma. This single centre, double-blind, placebo controlled, bilateral (split-face) comparison, was conducted on 44 Chinese subjects with chloasma during the winter season. The test formula was applied twice a day, for 12 weeks on left side of the face and a placebo formula on the right side of the face. Assessments included the use of the hemi-MASI (split-face Melasma Area Severity Index), both ultraviolet and standard photography, together with clinical evaluations of efficacy and safety at T0, T6 and T12 weeks. A significant difference between the 2-hemi-MASI was noticed after 6 and 12 weeks of treatment. This result was confirmed by the clinical evaluation of the dermatologists who recorded a significant improvement in the half-face treated with the new whitening formula compared with that treated with placebo (p = 0.003). The tolerance of the new formula was recorded as excellent by 82% of subjects and found to be cosmetically appealing. In this study, the new whitening formula containing ferulic acid, Ginkgo Biloba, lipohydroxyacid (LHA), niacinamide and thermal spring water was safe and significantly improved chloasma after a 3-month-treatment period compared with placebo.

Share and Cite:

Wang, X. , Li, Z. , Zhang, D. , Li, L. and Sophie, S. (2014) A Double-Blind, Placebo Controlled Clinical Trial Evaluating the Efficacy and Safety of a New Skin Whitening Combination in Patients with Chloasma. Journal of Cosmetics, Dermatological Sciences and Applications, 4, 92-98. doi: 10.4236/jcdsa.2014.42014.

Cited by

[1] Laser-assisted delivery of vitamin c or vitamin c plus growth factors in the treatment of chloasma in women: a systematic review and meta-analysis
… Assurance and Safety of Crops & …, 2022
[2] Effectiveness and safety of combined use of tranexamic acid and Xiyu dressing in chloasma therapy, and its effect on recurrence in patients
Tropical Journal of Pharmaceutical Research, 2022
[3] Methimazole in the Treatment of Melasma: A Clinical and Dermascopic Study.
2021
[4] Methimazole in the treatment of melasma: A clinical and dermascopic study
The Journal of …, 2021
[5] Microdermabrasion assisted delivery of glycolic acid 70% peel for the treatment of melasma in dark‐skinned patients
2021
[6] Modified Jessner's Solution Combined With Trichloroacetic Acid 20% Versus Glycolic Acid 70% Combined With Trichloroacetic Acid 20% in the Treatment of Melasma
2021
[7] Efficacy and safety of Tranexamic Acid 5% Cream vs Hydroquinone 4% Cream in Treating Melasma: A Split‐Face Comparative clinical, Histopathological and Antera …
2020
[8] Ascorbic Acid Derivative-Loaded Modified Aspasomes: Formulation, In-vitro, Ex-Vivo and Clinical Evaluation for Melasma Treatment
2019
[9] Depigmenting Agents
Pigmentary Skin Disorders, 2018
[10] Platelet-rich plasma is a useful therapeutic option in melasma
2018
[11] FORMULASI KRIM NIASINAMIDA TIPE M/A DENGAN FASE MINYAK MENGANDUNG VIRGIN COCONUT OIL (VCO)(VCO Kadar 15%, 20%, dan 25% dengan …
2017
[12] FORMULASI KRIM NIASINAMIDA TIPE M/A DENGAN FASE MINYAK MENGANDUNG VIRGIN COCONUT OIL (VCO)(VCO Kadar 2, 5%, 5%, dan 10% dengan …
2017
[13] 护肤品皮肤科应用指南
中国皮肤性病学杂志, 2015
[14] 阿魏酸对黑素细胞增殖, 黑素合成, 酪氨酸酶活性及 c-kit, ERK 蛋白表达的影响
中华皮肤科杂志, 2014
[15] 不同浓度阿魏酸溶液对人表皮黑素细胞增殖的影响
皮肤性病诊疗学杂志, 2014
[16] Archives of Biological and Biomedical Research
Motaleb, A Ghazally, 2012

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.